| Excerpt | Reference |
|---|
| "Fifteen patients with restless legs syndrome underwent whole-night polysomnographic recordings before and during clonazepam treatment." | ( Horiguchi, J; Inami, Y; Nishimatsu, O; Sasaki, A; Sukegawa, T, 1992) |
| "Thirty patients with restless legs syndrome, who initially had all responded well to treatment with levodopa and benserazide, were studied as to the long-term effect of the drugs (at least 2 years)." | ( Kempi, V; von Scheele, C, 1990) |
| "Seven patients suffering from restless legs syndrome (RLS) and periodic movements in sleep (PMS) were investigated before and after treatment with L-Dopa." | ( Bédard, MA; Godbout, R; Montplaisir, J; Poirier, G, 1986) |
| "We discuss a case of a patient with restless legs syndrome that was responsive to administration of amitriptyline." | ( Bamford, CR; Iacono, RP; Sandyk, R, 1988) |
| "Three patients with restless legs syndrome, two of whom also had nocturnal myoclonus, responded well to treatment with low doses of opioids." | ( Sateia, MJ; Trzepacz, PT; Violette, EJ, 1984) |
| "Ten patients with idiopathic restless leg syndrome (RLS) were asked to rate their symptoms at baseline during 2 weeks of placebo and 2 weeks of clonidine treatment by using a four-point scale." | ( Chokroverty, S; Coleman, RG; Grasing, K; Hening, WA; Wagner, ML; Walters, AS, 1996) |
| "Twenty patients with problematic restless legs syndrome (RLS) were treated with pergolide." | ( Shepard, JW; Silber, MH; Wisbey, JA, 1997) |
| "Eighteen patients with restless legs syndrome (RLS) and 4 patients with neuroleptic-induced akathisia (NIA) underwent all-night polysomnographic recordings before and during clonazepam treatment." | ( Horiguchi, J; Inami, Y; Katagiri, H; Nishimatsu, O; Sasaki, A; Sukegawa, T; Yamawaki, S, 1997) |
| "Since the treatment of restless legs syndrome (RLS) with levodopa or classical opioids is problematic, new treatment possibilities would be valuable." | ( Lauerma, H; Markkula, J, 1999) |
| "Thirteen consecutive patients with restless legs syndrome (RLS) were treated with piribedil and were rated using an RLS rating scale (0-10) and subjective response (0-100%); 11/13 (85%) had improvement of their mean RLS scores with subjective response ranging from 30% to 100% (mean 74." | ( Evidente, VG, 2001) |
| "Nine patients with idiopathic restless legs syndrome (RLS) were treated with 300 mg of gabapentin as an initial dose and an up-titration until relief of symptoms for 4 weeks." | ( Happe, S; Klösch, G; Saletu, B; Zeitlhofer, J, 2001) |
| "Current treatment options for restless legs syndrome (RLS), based on the American Academy of Sleep Medicine practice parameters, favor dopaminergic agents." | ( Stiasny, K, 2001) |
| "Twenty patients with idiopathic restless legs syndrome (RLS) were treated with 600 mg slow-release VPA and 200 mg slow-release LD+50mg benserazid in a randomized, placebo-controlled, cross-over, double-blind setting with polysomography (PSG) at the end of each 3-week treatment periods." | ( Ehrenberg, BL; Eisensehr, I; Noachtar, S; Rogge Solti, S, 2004) |
| "The cause of restless legs syndrome (RLS) is unknown, but an involvement of the dopaminergic system and a possible relation to Parkinson's disease (PD) is suggested by the positive response to dopaminergic treatment." | ( Eisensehr, I; Gildehaus, FJ; Linke, R; Noachtar, S; Pöpperl, G; Tatsch, K; Trenkwalder, C; Wetter, TC, 2004) |
| "Treatment of restless legs syndrome with dopaminergic medications is highly effective, although augmentation may occur eventually and require dosing flexibility." | ( Ondo, WG, 2005) |
| "Patients with moderate to severe restless legs syndrome (RLS) were randomly assigned to cabergoline (single evening dose: 2 mg) or placebo and treated for 5 weeks in a double-blind, multicenter polysomnography (PSG) trial." | ( Benes, H; Bodenschatz, R; Cassel, W; Geisler, P; Happe, S; Kohnen, R; Leroux, M; Oertel, WH; Peglau, I; Stiasny-Kolster, K; Warmuth, R, 2006) |
| "Treatment of restless legs syndrome with ropinirole shows it to be effective, well-tolerated and safe and it can be used in restless legs syndrome in general." | ( Fornadi, K; Molnar, MZ; Shapiro, CM, 2006) |
| "Algorithms for treatment of restless legs syndrome (RLS) include both nonpharmacologic and pharmacologic therapy." | ( Hening, WA, 2007) |
| "After observing improvement of restless legs symptoms in seven patients treated with pregabalin for neuropathic pain, we extended the clinical observation to a total of 16 patients with secondary RLS, in most of them due to neuropathy, and to three patients with idiopathic RLS." | ( Bachmann, CG; Liebetanz, KM; Paulus, W; Schindehütte, J; Sommer, M; Tings, T, 2007) |
| "We report a case of restless legs syndrome that improved after intravenous magnesium sulfate administration." | ( Bartell, S; Zallek, S, 2006) |
| "The impressive relief from restless legs syndrome (RLS) symptoms provided by levodopa treatment indicates RLS is caused by a dopaminergic abnormality." | ( Allen, RP; Earley, CJ, 2007) |
| "Relief of restless legs symptoms marked on a validated scale, subjective sleep quality, sleep quality measured by night polysomnography and actigraphy, quality of life measured by subjective measures, adverse events associated with the treatments." | ( Andriolo, RB; Atallah, AN; Coin de Carvalho, LB; Conti, CF; de Oliveira, MM; do Prado, GF; Saconato, H; Valbuza, JS, 2007) |
| "Treatment of restless legs syndrome (RLS) has as its goals alleviation of the primary symptoms of the disorder and establishment of normal sleep." | ( Allen, RP; Hening, W; Tenzer, P; Winkelman, JW, 2007) |
| "Intrathecal opiates for restless legs syndrome are currently considered investigational, but we hope, with this second report of the efficacy of low-dose intrathecal narcotics in this condition, to stimulate further investigation of this treatment modality." | ( Narus, MS; Nutt, JG; Ross, DA, 2008) |
| "This update on restless legs syndrome (RLS) focuses on its pathophysiology, genetics, health impact, and treatment." | ( Bhadriraju, S; Rye, DB; Trotti, LM, 2008) |
| "Patients with Restless Legs Syndrome (RLS) often seek treatment because of sleep problems related to nocturnal symptoms." | ( Aarskog, D; Albrecht, S; Chaudhuri, KR; Ferini-Strambi, L; Partinen, M; Sohr, M; Verri, D, 2008) |
| "To assess the prevalence of Restless Legs Syndrome (RLS) in anemic patients with Congestive Heart Failure (CHF) and Chronic Renal Failure (CRF) and to evaluate the effect of anemia treatment on RLS." | ( Oksenberg, A; Schwartz, D; Silverberg, DS; Zilberman, M, 2010) |
| "We report a case of severe restless legs syndrome (RLS) that occurred as a side effect of olanzapine therapy." | ( Khalid, I; Khalid, TJ; Rana, L; Roehrs, T, 2009) |
| "That restless legs can occur simultaneously in a phantom as well as a real limb and that the perception of movement in a phantom limb as well as dopaminergic treatment improved the symptoms provides further support for the important role of central nervous system dysfunction in the development of this disorder." | ( Drago, V; Foster, PS; Heilman, KM; Skidmore, FM, 2009) |
| "The European Restless Legs Syndrome (RLS) Study Group performed the first multi-center, long-term study systematically evaluating RLS augmentation under levodopa treatment." | ( Allen, RP; Benes, H; de Weerd, A; Egatz, R; Ferini-Strambi, L; Frauscher, B; García-Borreguero, D; Gschliesser, V; Hadjigeorgiou, G; Happe, S; Hening, WA; Högl, B; Hornyak, M; Kohnen, R; Stiasny-Kolster, K; Trenkwalder, C, 2010) |
| "The first step in the management of restless legs syndrome (RLS) is to identify, and if possible to treat any condition which might cause or worsen RLS, such as iron deficiency or some drug treatments." | ( Haba-Rubio, J; Krieger, J, 2010) |
| "Comorbid depressive symptoms in restless legs syndrome (RLS) remain a treatment challenge, as some antidepressants aggravate RLS symptoms." | ( Banik, N; Benes, H; Bergmann, L; Dreykluft, T; Hansen, C; Hornyak, M; Kohnen, R; Mattern, W; Peglau, I; Schoen, SW, 2011) |
| "Because of the subjective nature of Restless Legs Syndrome (RLS) symptoms and the impact of these symptoms on sleep, patient-reported outcomes (PROs) play a prominent role as study endpoints in clinical trials investigating RLS treatments." | ( Bhanegaonkar, A; Bharmal, M; Calloway, M; Canafax, DM, 2011) |
| "International Restless Legs Scale (IRLS) scores were measured for all patients at baseline and at the end of treatment phase." | ( Akbari, H; Behzadi, S; Dormanesh, B; Fallahzadeh, MK; Heydari, ST; Sagheb, MM; Sohrabi Nazari, S, 2012) |
| "Outpatients with RLS (International Restless Legs Syndrome Rating Scale (IRLS) scores ≥15) were randomized (n = 474) and treated (n = 469) in a double-blind manner with once-daily placebo (n = 116), 600 (n = 120), 900 (n = 119) or 1200 (n = 114) mg GEn for 12 weeks." | ( Hattori, N; Hirata, K; Inoue, Y; Kuroda, K; Takeuchi, M; Uchimura, N, 2013) |
| "We report on seven cases of restless legs syndrome (RLS) in patients treated with quetiapine." | ( Rittmannsberger, H; Werl, R, 2013) |
| "To describe symptoms of restless legs syndrome (RLS) in early childhood and the effect of oral iron treatment." | ( Norregaard, O; Ostergaard, JR; Tilma, J; Tilma, K, 2013) |
| "The diagnosis of restless legs syndrome (RLS) relies upon diagnostic criteria which are based on history only, and dopaminergic treatment is not normally the first choice of treatment for all patients." | ( Bassetti, CL; Baumann, CR; Cippà, MA; Poryazova, R; Siccoli, MM; Werth, E, 2013) |
| "Usually symptoms of restless legs syndrome (RLS) respond well to treatment with dopaminergic drugs, opiates, or anticonvulsant medications." | ( Gross, N; Schulte, EC; Slawik, H; Winkelmann, J, 2013) |
| "We present a familial case of severe restless legs syndrome (RLS) resistant to polytherapy who showed a consistent and effective amelioration of RLS symptoms after introduction of varenicline as antismoking drug." | ( Romigi, A; Vitrani, G, 2013) |
| "The symptoms of restless legs syndrome (RLS) can be managed effectively by treatment." | ( Hirata, K; Suzuki, K, 2013) |
| "We investigated the prevalence of restless legs syndrome (RLS) in Japanese patients with type 2 diabetes and assessed the efficacy of pramipexole therapy." | ( Harashima, S; Inagaki, N; Liu, Y; Nishimura, A; Osugi, T; Takayama, H; Wang, Y, 2016) |
| "Lack of a valid diagnostic measure of restless legs syndrome (RLS) for persons with dementia, who do not have the cognitive ability to report complex symptoms, impedes RLS treatment and research in this population." | ( Allen, RP; Beck, CK; Bliwise, DL; Bost, JE; Cuellar, N; Hutchison, LC; Kovach, CR; Richards, KC; Rogers, VE, 2015) |
| "Idiopathic restless legs syndrome (RLS) can severely affect quality of life and disturb sleep, so that pharmacological treatment is necessary, especially for elderly patients." | ( Inoue, Y; Paulus, W; Trenkwalder, C; Winkelmann, J, 2015) |
| "Few studies have investigated restless legs syndrome (RLS) treatment effects on individual International RLS Study Group Rating Scale (IRLS) items." | ( Ahmed, M; Hays, R; Jaros, MJ; Kim, R; Shang, G; Steven Poceta, J, 2016) |
| "As the restless legs syndrome, the restless arms syndrome can be exacerbated by perioperative procedures and improved with pramipexole from the first day of treatment." | ( Cotte, E; Dondé, C; Gonnaud, PM; Peter-Derex, L; Pitance, F; Saoud, M, 2017) |
| "Treating patients with restless legs syndrome (RLS) may pose a significant challenge to the clinician if those with intractable disease worsen with chronic treatment." | ( Rubin, M, 2017) |
| "Newer clinical guidelines for restless legs syndrome are increasingly recommending the α2δ ligands as a logical first-choice medication for patients needing drug therapy for symptom control." | ( Faulkner, MA, 2018) |
| "Augmentation can occur frequently in restless legs syndrome (RLS) patients treated with dopaminergic agents." | ( Muntean, ML; Sixel-Döring, F; Steinke, SS; Trenkwalder, C; Zimmermann, J, 2018) |
| "Our objective is to determine whether Restless Legs Syndrome (RLS), that has been associated with more impulsive choices in general population regardless of dopaminergic therapy, could be associated with a specific psycho-behavioral profile and ICDs in PD." | ( Beudin, P; Debilly, B; Derost, P; Durif, F; Fantini, ML; Figorilli, M; Marques, A; Pereira, B; Vidal, T, 2018) |
| "Patients suffering from itching, restless legs syndrome, persistent asthenia or malnourishment could benefit from HDx therapy." | ( Florens, N; Juillard, L, 2018) |
| "Treatment with pramipexole is used in restless legs syndrome." | ( Esteves, AM; Franco, B; Holanda, ASS; Manconi, M; Morais, MA; Simino, LAP; Torsoni, A, 2021) |
| "Low dosage DA, as given when treating restless legs syndrome (RLS), has been thought only to have mild side effects." | ( Ibsen, JD; Lindström, ES; Skovbølling, SL, 2022) |
| "Patients with Parkinson's disease, restless legs syndrome and other conditions potentially treated with dopamine agonists, as well as patients treated for psychotic disorders, are vulnerable patient groups with theoretically increased risk of developing gambling disorder (GD), for example due to higher rates of mental ill-health in these groups." | ( Håkansson, A; Wolfschlag, M, 2023) |
| "The pathomechanism of restless legs syndrome (RLS) is related to brain iron deficiency and iron therapy is effective for RLS; however, the effect of iron therapy on human brain iron state has never been studied with magnetic resonance imaging." | ( Byun, JI; Gho, SM; Jun, JS; Jung, KY; Kim, JH; Kim, MH; Kim, TJ; Shin, JW; Sohn, CH; Sunwoo, JS, 2023) |